Results 141 to 150 of about 2,314,591 (317)
Selective Association of Sindbis Virion Proteins with Different Membrane Fractions of Infected Cells [PDF]
Henry R. Bose, M. A. Brundige
openalex +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
Correlating membrane-protein dynamics with function: Integrating bioinformatics, molecular dynamics, and single-molecule FRET. [PDF]
Higinbotham HR, Arbour CA, Imperiali B.
europepmc +1 more source
Electrophoretic Patterns of Membrane Proteins of Mycoplasma
Shlomo Rottem, Shmuel Razin
openalex +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
Rules of Engagement for Components of Membrane Protein Biogenesis at the Human Endoplasmic Reticulum. [PDF]
Zimmermann R.
europepmc +1 more source
Multiple protein components of mammalian cell membranes.
E. D. Kiehn, John J. Holland
openalex +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
Structure of the membrane protein of influenza virus. I. Isolation and characterization of cyanogen bromide cleavage products [PDF]
Betty H. Robertson +3 more
openalex +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source

